A Phase 4 clinical trial involving icatibant has been updated to completed status as of August 11, 2026. The trial, registered as NCT04113109, is titled "Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2." This study is classified as Phase 4, indicating it was conducted after the relevant treatment or combination had already received approval. The record identifies the trial's status change to completed but does not provide additional detail on findings or outcomes. Icatibant remains an approved compound, and this update reflects only the administrative status of the trial listing. No results, efficacy data, or safety conclusions are included in this update. Readers seeking further detail on the trial's design or scope can consult the official registration at the provided identifier. For general background on icatibant, including its approved uses and mechanism, readers can refer to the compound overview.
Icatibant Trial NCT04113109 Marked Completed on Aug 11, 2026
See the full icatibant overview
Source: https://clinicaltrials.gov/study/NCT04113109